Education and Training
Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
The purpose of this study is to investigate the safety and efficacy of memantine extended release, as well as its extent of absorption in pediatric patients with autism.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Placebo
- drug: Memantine - Extended Release (ER)
Eligibility
Inclusion Criteria:
- Males or females ages 6 to 12 years
- Diagnosis of autistic disorder, according to DSM-IV-TR using Autism Diagnostic
Interview-Revised and Autism Diagnostic Observation Schedule (modules 2 & 3).
- A knowledgeable caregiver capable of providing reliable information about the
patient's condition, able to attend all clinic visits with the patient
- Patients over age 12, only if they completed Study MEM-PK-21
Exclusion Criteria:
- Medical history of active epilepsy/seizure disorder except simple febrile seizures
- Participation in any other clinical investigation using an experimental drug within 30
days of the start of this study
Ages Eligible for Study
6 Years - 18 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Robin Libove
6507361235
Not Recruiting